Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials.

The number of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) implantations is increasing drastically worldwide, and hence, the number of implanting centers is also increasing. Despite abundant data on the beneficial effect of these devices, little is known regarding safety and complication rates. Eleven ICD and 7 CRT trials were systematically reviewed to provide data on the frequency of in-hospital mortality and complications related to the implantation. Average in-hospital mortality was 2.7% in trials using both thoracotomy and nonthoracotomy ICDs, 0.2% in trials using nonthoracotomy ICDs, and 0.3% in CRT trials. The pneumothorax rate was similar between the nonthoracotomy ICD and CRT trials (0.9%) Coronary sinus complications occurred in 2.0% of patients undergoing CRT. Lead dislodgement rates were higher in CRT trials (5.7%) than in nonthoracotomy ICD trials (1.8%).

[1]  A. Khasnis,et al.  Prophylactic Defibrillator Implantation in Patients With Nonischemic Dilated Cardiomyopathy , 2004 .

[2]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[3]  Bigger Jt,et al.  Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery , 1997 .

[4]  R. Hauser,et al.  The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. , 2005, Journal of the American College of Cardiology.

[5]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[6]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[7]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[8]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[9]  R. Cappato,et al.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.

[10]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[11]  P. Tchou,et al.  Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. , 2007, The New England journal of medicine.

[12]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[13]  Q. Fang,et al.  [Combined cardiac resynchronization and implantable cardioversion defibrillation]. , 2005, Zhonghua xin xue guan bing za zhi.

[14]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[15]  M. Eldar,et al.  Comparison of results with different left ventricular pacing leads. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  B. Wilkoff,et al.  Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. , 2001, American heart journal.

[17]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[18]  J. Daubert,et al.  Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. , 2005, Journal of the American College of Cardiology.

[19]  M. Rich,et al.  Implantable cardiac device procedures in older patients: use and in-hospital outcomes. , 2010, Archives of internal medicine.

[20]  G. Tenderich,et al.  Left Heart Pacing—Experience with Several Types of Coronary Vein Leads , 2002, Journal of Interventional Cardiac Electrophysiology.

[21]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[22]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[23]  P. Belott.  How to access the axillary vein. , 2006, Heart rhythm.

[24]  Ó. Cano,et al.  Defibrillator implantation early after myocardial infarction. , 2010, The New England journal of medicine.

[25]  P. Heidenreich,et al.  Gender Differences in Procedure-Related Adverse Events in Patients Receiving Implantable Cardioverter-Defibrillator Therapy , 2009, Circulation.

[26]  A. Wilde,et al.  Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation? , 2007, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[27]  Riccardo Cappato,et al.  Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest The Cardiac Arrest Study Hamburg (CASH) , 2000 .

[28]  D. Cohen,et al.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. , 2006, Journal of the American College of Cardiology.

[29]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[30]  J. Daubert,et al.  Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[31]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[32]  J. Curtis,et al.  Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. , 2010, Journal of the American College of Cardiology.

[33]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[34]  Jacques Victor,et al.  Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-Defibrillators: Results of a Large Prospective Study , 2007, Circulation.

[35]  J. Daubert,et al.  Six year experience of transvenous left ventricular lead implantation for permanent biventricular pacing in patients with advanced heart failure: technical aspects , 2001, Heart.

[36]  F. Morady,et al.  A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. , 2000, Journal of the American College of Cardiology.